Delcath Systems, Inc. · NASDAQ:DCTH
Delcath Systems — Shareholder Meeting (June 2017)
13 slides from Delcath Systems's shareholder meeting presentation, Jun 5, 2017
Slide 1: Delcath Annual Shareholder Meeting
Delcath Annual Shareholder Meeting (NASDAQ: DCTH) June 5, 2017 Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expectations, beliefs, plans, objectives, intentions, goals, strategies, a
Slide 3: 2016/2017 Highlights
2016/2017 Highlights 2016 revenue increased 18% to $2.0 million; Q1 2017 increased 100% to $0.74 million; National reimbursement coverage in Germany under ZE system; 2016 SPA agreement and initiation of Phase 3 Trial in treatment of patients with ocular melanoma liver metastases 2017 SPA agreement w
Slide 4: Shareholder Value Through Clinical Development Program
Shareholder Value Through Clinical Development Program Tumor Type Milestones 201 HCC Trial (US Only) 202 HCC/ICC Trial (EU Only) ICC Data Release FOCUS Trial P3 Pivotal Study in Hepatic Dominant OM Interim Safety Analysis end 2017 FDA 2019 Ocular Melanoma (OM) Hepatocellular Carcinoma (HCC) Intrahep
Slide 5: Recent Data Provides Confidence: Hepatic Progression-free and Overall Survival
Recent Data Provides Confidence Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma, Moffitt Cancer Center (AJCO) Analysis of 3 non-randomized approaches for treatment of 30 patients with liver metastases primarily resulting from ocular melanoma
Slide 6: Recent Data Provides Confidence: PHP for Metastatic Ocular Melanoma
Recent Data Provides Confidence Percutaneous Hepatic Perfusion (PHP) for unresectable metastatic ocular melanoma to the liver: A Multi-institutional report of outcomes – Moffitt Cancer Center, University Hospital Southampton (Regional Therapies Symposium 2017) 49 PTS treated between 2008 and 2016; P
Slide 7: Global Pivotal Trial in ICC
Global Pivotal Trial in ICC Melphalan/HDS TX every 6-8 weeks ≤ 6 cycles GEM/CIS Re-Induction Primary Endpoint (Overall Survival) Secondary Endpoints (Progression Free Survival, Objective Response Rate, Safety) Screening Phase (N=295) R 1:1 Leveraging existing network of participating centers in Phas
Slide 8: CDP Focused on Fastest Path to U.S. Market
CDP FOCUSED ON FASTEST PATH TO U.S. MARKET EU & US TAM Cancer Type Annual Incidence1 Eligible PTS2 Annual Potential Market Opportunity (Millions)3,4 Ocular Melanoma ~4,700 ~2,000 ~$80-$200 Intrahepatic Cholangiocarcinoma (ICC) ~14,000 ~9,300 ~$372-$930 Hepatocellular Carcinoma (HCC) 64,500 7,600-14,
Slide 9: European Commercialization
European Commercialization Presence established in several major markets (~22 cancer centers) National reimbursement established after <3 years of commercial activity European centers producing data to support reimbursement applications in additional markets Commercial sales growing steadily; expand
Slide 10: European Commercialization
European Commercialization ~400 commercial procedures performed EU Physicians opting to retreat patients as familiarity/confidence grows UK Patient received record 8th TX in March 2017; SPIRE Southampton performed >100 TX Established network of treating centers participating in pivotal trials Data f
Slide 11: Convertible Note
Convertible Note $35.0 million senior secured convertible notes issued June 2016 subject to certain equity conditions Provided resources necessary for advancement of CDP where we believe shareholder value will be realized Recently executed warrant repurchase agreements with note holders; agreement f
Slide 12: Cash & Capital Resources
Cash & Capital Resources Cash & Cash Equivalents $6.4 million at March 31, 2017 Debt $21.8 million at March 31, 2017 Restricted Cash $20.7 million at March 31, 2017 Shares Outstanding 167,883,231 million (168.5 million fully diluted1)2 at May 8, 2017 Fully diluted includes approximately 0.1 million
Slide 13: Concentrating the Power of Chemotherapy
Concentrating the Power of Chemotherapy™ INC. ALL